Merck halts more trials of HIV candidate islatravirMerck & Co has halted enrolment in a pair of phase 3 trials of its experimental HIV drug Share XMerck halts more trials of HIV candidate islatravirhttps://pharmaphorum.com/news/merck-halts-more-trials-of-hiv-candidate-islatravir/
Merck claims another adjuvant okay from FDA for KeytrudaMerck & Co’s strategy of pushing Keytruda earlier in the treatment pathway for cancers has secured anther victory, Share XMerck claims another adjuvant okay from FDA for Keytrudahttps://pharmaphorum.com/news/merck-claims-another-adjuvant-okay-from-fda-for-keytruda/
Truepill preps launch of virtual COVID-19 service for oral antiviralsTelehealth, diagnostics and pharmacy business Truepill will launch a new virtual care platform in the coming weeks that Share XTruepill preps launch of virtual COVID-19 service for oral antiviralshttps://pharmaphorum.com/news/truepill-preps-launch-of-virtual-covid-19-service-for-oral-antivirals/
Merck’s oral COVID drug squeaks past FDA advisory committeeAn FDA advisory committee voted by 13 to 10 to recommend emergency-use authorisation for Merck & Co and Share XMerck’s oral COVID drug squeaks past FDA advisory committeehttps://pharmaphorum.com/news/mercks-oral-covid-drug-squeaks-past-fda-advisory-committee/
AZ eyes FDA verdict on Lynparza in adjuvant breast cancer in Q1The FDA will deliver a verdict on AstraZeneca’s PARP inhibitor Lynparza as an adjuvant treatment for breast cancer Share XAZ eyes FDA verdict on Lynparza in adjuvant breast cancer in Q1https://pharmaphorum.com/news/az-eyes-fda-verdict-on-lynparza-in-adjuvant-breast-cancer-in-q1/
Fall in efficacy of Merck’s molnupiravir puts Pfizer in driver’s seatMerck & Co has reported new data with its oral antiviral molnupiravir that suggests it is not as Share XFall in efficacy of Merck’s molnupiravir puts Pfizer in driver’s seathttps://pharmaphorum.com/news/fall-in-efficacy-of-mercks-molnupiravir-puts-pfizer-in-drivers-seat/
Pfizer gets bumper $5.3bn order from US for oral COVID drugAlready making big profits from its COVID-19 vaccine, Pfizer looks set to bolt on another big revenue stream Share XPfizer gets bumper $5.3bn order from US for oral COVID drughttps://pharmaphorum.com/news/pfizer-gets-bumper-5-3bn-order-from-us-for-oral-covid-drug/
Merck wins FDA nod for Keytruda as adjuvant kidney cancer treatmentMerck & Co has chalked up another win in drive to move PD-1 inhibitor Keytruda earlier in the Share XMerck wins FDA nod for Keytruda as adjuvant kidney cancer treatmenthttps://pharmaphorum.com/news/merck-wins-fda-nod-for-keytruda-as-adjuvant-kidney-cancer-treatment/
Merck’s oral PCSK9 drug matches injectables in early trialsInjectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Share XMerck’s oral PCSK9 drug matches injectables in early trialshttps://pharmaphorum.com/news/mercks-oral-pcsk9-drug-matches-injectables-in-early-trials/
